China's First Large-Scale Medical Humanities Documentary on Hematology Development Launched at the Third CIIE

Shanghai, November 6, 2020 /PRNewswire/ -- Today, the launch of China’s first large-scale medical humanities documentary, “Innovation and Breakthroughs: A History of Hematology Development in China,” was announced at the Takeda Pharmaceutical booth during the Third China International Import Expo. The documentary was jointly planned by the Hematology Branch of the Chinese Medical Association, the Beijing Kangmeng Charity Foundation, and Takeda China, with media strategic support provided by Southern Weekly. The documentary will review the development of hematology in China over the past four decades, aiming to commemorate the academic elegance and outstanding achievements of generations of Chinese hematology researchers, while looking ahead to the future direction of hematology in China. In addition to promoting industry progress, it will also play a positive role in advancing the cause of healthcare in China.

Professor Wu Depei, Chairman of the Chinese Society of Hematology under the Chinese Medical Association and Director of the Department of Hematology at the First Affiliated Hospital of Soochow University; Professor Ma Jun, Director of the Harbin Institute of Hematology and Oncology and Chairman of the Supervisory Board of the Chinese Society of Clinical Oncology (CSCO); Ms. Liu Ying, Chairperson of the Beijing Kangmeng Charity Foundation;Mr. Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical Company Limited and President of Takeda China; Mr. Zhu Qiang, Deputy Editor-in-Chief of Southern Weekly, and other distinguished guests jointly attended the launch ceremony, engaging in discussions on the developmental history of hematology specialties in China and breakthroughs in diagnostic and therapeutic technologies for hematologic diseases, while looking ahead to the future innovative prospects of the discipline in China.

Guests at the event jointly attended the launch ceremony

At the launch ceremony, Professor Wu Depei, Chairman of the Hematology Branch of the Chinese Medical Association and Director of the Department of Hematology at the First Affiliated Hospital of Soochow University, delivered a speech. He stated, “The vigorous development of hematology in China over the past four decades has been inseparable from the joint efforts of the government, experts and scholars, corporate partners, and all sectors of society. Today, we are delighted to leverage the China International Import Expo (CIIE) as an innovative platform that fosters win-win cooperation, and to join hands with numerous partners—including the Beijing Kangmeng Charity Foundation, Takeda China, and Southern Weekly—to co-produce a documentary showcasing the milestone developments and transformations in China’s hematology field over the decades. We look forward to further advancing the cause of hematology in China by better integrating resources and leveraging complementary strengths.”

Address by Professor Wu Depei, Chairman of the Hematology Branch of the Chinese Medical Association and Director of the Department of Hematology at the First Affiliated Hospital of Soochow University

Hematology is an independent branch of medical science, primarily focusing on blood and hematopoietic tissues. Over the past 40-plus years since the reform and opening-up policy was implemented, China has achieved numerous breakthroughs in both basic research and clinical practice in hematology. Since the establishment of the Hematology Branch of the Chinese Medical Association, under the leadership of its successive committees, the field of hematology in China has witnessed vigorous development, inMultiple sub-ProfessionalThe field has achieved a leap from nonexistence to existence and from weakness to strength. The influence of Chinese hematology experts in the international academic community is gradually increasing, and the diagnosis and treatment technologies for hematologic diseases have reached the international forefront in many areas, helping numerous Chinese patients with hematologic disorders improve their quality of life and achieve long-term survival.

Ms. Liu Ying, Chairperson of the Beijing Kangmeng Charity Foundation, stated, “Over the past four decades, through the exploration and dedication of generations of hematologists, basic and clinical research in hematology in China has continuously deepened, achieving qualitative improvements in both academic and technical standards, while growing international influence. As a charitable organization, the Beijing Kangmeng Charity Foundation is committed to advancing the medical humanities in hematology. By producing documentaries on the history of hematology’s development, we can document the innovative journey of China’s rapidly advancing hematology sector. This effort facilitates the accumulation of hematology’s historical legacy and promotes the dissemination of medical humanities knowledge related to hematology to the broader society, thereby holding significant importance and playing a vital role in fostering the development of medical humanities in hematology in China.”

Address by Ms. Liu Ying, Chairperson of the Board of Directors, Beijing Kangmeng Charity Foundation

Professor Ma Jun, Director of the Harbin Institute of Hematology and Oncology and Chairman of the Board of Supervisors of the Chinese Society of Clinical Oncology (CSCO), stated, “The production of a documentary on the history of hematology development in China is a major event for the entire Chinese hematology community. It is a privilege to participate in this international platform for innovative exchange at the China International Import Expo (CIIE) and to share with the world the latest breakthroughs in the development of Chinese hematology. In recent years, the diagnosis and treatment standards in China’s hematology field have achieved leapfrog development, aligning with international therapeutic practices. Numerous innovative technologies continue to drive the implementation of the ‘Healthy China’ strategy. Moving forward, we will continue to seize opportunities, uphold the pioneering spirit of our predecessors in hematology, and strive tirelessly to promote the sustained development of hematology and improve patients’ overall survival and quality of life.”

Address by Professor Ma Jun, Director of the Harbin Institute of Hematology and Oncology, and Chairman of the Supervisory Board of the Chinese Society of Clinical Oncology (CSCO)

Mr. Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical Company Limited and President of Takeda ChinaTakeda stated, “It is an honor for Takeda to participate in this collaboration. We believe that holding the launch ceremony of this documentary at the China International Import Expo (CIIE)—a platform that encourages collaborative innovation and supports international exchanges—will further promote international medical research communication, focus on the latest cutting-edge technologies in global medical diagnosis and treatment, and advance disciplinary development. We look forward to contributing to the progress of hematology in China through the filming of this documentary, thereby making a contribution to the advancement of China’s healthcare industry.”

Address by Mr. Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical Company Limited and President of Takeda China

About Takeda
Takeda (Tokyo Stock Exchange Ticker Symbol: 4502(NYSE: TAK) is a Japan-headquartered, values-based, R&D-driven global leading biopharmaceutical company. Takeda is committed to translating scientific research achievements into highly innovative medicines, safeguarding patients’ healthy lives and promising future. Takeda focuses on drug development in four therapeutic areas: oncology, gastroenterology, neuroscience, and rare diseases, with dedicated R&D investments in plasma-derived therapies and vaccines. We remain steadfastly focused on developing highly innovative medicines by pioneering novel treatment approaches and strengthening our collaborative R&D engine, thereby building a robust and diverse product pipeline that helps improve people’s lives. Our employees are present in approximately 80 countries and regions, working hand-in-hand with local healthcare partners to deliver health benefits to patients worldwide.

Takeda entered China in 1994. Takeda’s China headquarters is located in Shanghai, with major business centers in Beijing, Shanghai, Tianjin, Guangzhou, and Hong Kong. The company maintains offices in key cities across China and currently employs nearly 2,000 people in the country. With China’s economic development and the growing demand for healthcare, China has become one of Takeda’s most important emerging markets globally.

For more information, please visithttps://www.takeda.com